Consonance Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Consonance Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,706,426	Closed	-$98.2M	–	41
2020 Q2	$98.2M	Sell	1,706,426 -591,353	-26%	-$32.2M	5.88%	5
2020 Q1	$92.3M	Buy	2,297,779 +396,112	+21%	+$16.8M	6.87%	4
2019 Q4	$75.2M	Buy	1,901,667 +235,000	+14%	+$4.13M	4.59%	6
2019 Q3	$11.3M	Hold	1,666,667	–	–	1.12%	22
2019 Q2	$15.5M	Hold	1,666,667	–	–	1.1%	22
2019 Q1	$23.1M	Buy	+1,666,667	New	+$19.1M	1.46%	19

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Consonance Capital Management's CCXI Position: Q3 2020 in Review

Consonance Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2020, closing a stake of 1,706,426 shares — an estimated $98.2M sold.

Consonance Capital Management first reported a position in CCXI in Q1 2019 and held it in 6 quarters. The position peaked at $98.2M in Q2 2020. 204 funds tracked by Wall St. Rank hold CCXI as of Q3 2020.

Consonance Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2020 after selling out during the quarter.
Consonance Capital Management sold 1,706,426 ChemoCentryx, Inc. shares in Q3 2020, an estimated $98.2M.
Consonance Capital Management first reported a position in ChemoCentryx, Inc. in Q1 2019 and held it in 6 quarters.
Consonance Capital Management's ChemoCentryx, Inc. position peaked at $98.2M in Q2 2020.
204 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2020.

Based on Consonance Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.